louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03363802: Assessment of Pubertal Growth Spurt in Growing Girls Using Middle Phalynx Finger and Correlate With Mandibular Second Molar
Official title: Assessment of Pubertal Growth Spurt in Growing Egyptian Females Using Modified Middle Phalanx of The Middle Finger Stages and Its Correlation With Development Stage of Mandibular Second Molar in Al Sharkia Governorate
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Growth Alteration
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-12-06
Enrollment: 1600
Sex: FEMALE
Minimum age (years): 9
Maximum age (years): 14
Standard ages: CHILD
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Egyptian females between 9-14 years old to be sure that they are within or around the circumpubertal period.

Brief summary: Assessment of Pubertal Growth Spurt in Growing Egyptian Females Using Modified Middle Phalanx of The Middle Finger Stages and Its Correlation With Development Stage of Mandibular Second Molar

Detailed description: The sample will be selected randomly from different schools in the government.

* Digital periapical radiograph for the middle finger for each participants will be taken using Digital x-ray portable machine.
* Radiographical images will be stored in a digital sensor to be transferred to computer then we asses growth spurt in girls and correlate it with devlopemt stage of mandibular second molar

Eligibility criteria: Inclusion Criteria:

* Egyptian citizen

Exclusion Criteria:

* Systemic disease and syndromes
* Severe crowding

Primary outcomes:
measure: Assessment of the time of pubertal growth spurt in growing Egyptian
timeFrame: 3month
Secondary outcomes:
measure: females. Assessment the correlation between the modified middle phalanx of the middle finger and development stage of mandibular second molar
timeFrame: 3month
Other outcomes:
Locations:
city: Zagazig
country: Egypt
facility: Schools
state: Sharkia Governorate
Study officials:
References:
Clinical trial NCT03941002: Continuous Evaluation of Diaphragm Function
Official title: Continuous Evaluation of Diaphragm Function During Assisted Mechanical Ventilation in Critically Ill Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Respiration, Artificial
Mechanical Ventilation
Critical Illness
Lead sponsor: University of Milan
Sponsor class: OTHER
First posted: 2019-05-07
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Aim of mechanical ventilation is to improve gas exchange and to unload the respiratory muscles delivering a form of mechanical support to the ventilation. At the same time, it is essential that the support is individually-tailored to avoid the development of muscular atrophy, a process called "ventilatory-induced diaphragm dysfunction"

Aim of the present study is that the continuous ultrasonographic assesment of diaphragm function, as obtained by the device under investigation (DiaMon, Respinor AS, Oslo, Norway) is related to the degree of effort of inspiratory muscles, as measured by gold-standard indices such as esophageal and gastric pressure measurement.

A secondary aim is that the data assessed by the device are related to a standard ultrasonographic examination performed by expert operators.

In particular, we will enroll a population of critically ill patients undergoing mechanical ventilation in assisted mode, and we will perform a decremental pressure support trial, with the following aims:

1. to evaluate the performance of a continuous and automated device for the monitoring of diaphragm contractile activity, as compared to standard mechanical indices of respiratory effort such as the pressure-time product (PTP)
2. to evaluate the performance of a continuous and automated device for the monitoring of diaphragm contractile activity, as compared to the ultrasonographic assesment of muscle function performed by an expert operator.


Eligibility criteria: Inclusion Criteria:

* Acute respiratory failure which necessitated endotracheal intubation and mechanical ventilation, with ventilation in pressure-support mode.
* Positive end-expiratory pressure (PEEP) lower than 10 cmH2O
* Pressure support level between 4 and 10 cmH2O
* Ratio between PaO2 and FiO2 \>200 mmHg
* Resolution of the cause of respiratory failure

Exclusion Criteria:

* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
* Pregnancy
* Circulatory failure

Primary outcomes:
measure: Diaprhagm excursion
timeFrame: Study 1 day
Secondary outcomes:
measure: Esophageal pressure swing
timeFrame: Study 1 day
measure: Pressure-time product
timeFrame: Study 1 day
measure: Pressure-time product
timeFrame: Study 1 day
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Ospedale San Paolo - Polo Universitario, ASST Santi Paolo e Carlo
state: MI
Study officials:
References:
Clinical trial NCT01188902: The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women
Official title: The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Ludwig-Maximilians - University of Munich
Sponsor class: OTHER
First posted: 2010-08-26
Enrollment: 60
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objectives of the proposed study are to assess the effect of walnut consumption on parameters of lipid metabolism, glucose metabolism, incretins and adipokines, endothelial function and blood pressure in healthy men and healthy postmenopausal women


Eligibility criteria: Inclusion Criteria:

* Postmenopausal healthy women and healthy men
* Age \> 50 yrs

Exclusion Criteria:

* Evidence of alcohol, tabacco or drug abuse
* Obesity ≥ 35 kg/m2
* Diabetes mellitus
* Hypertension
* LDL-cholesterol \> 190 mg/dl, Triglycerides \> 350 mg/dl
* History of atherosclerotic disease

Primary outcomes:
measure: Fasting non-HDL-cholesterol
timeFrame: 8 weeks
Secondary outcomes:
measure: area under the triglyceride curve (AUC-TG)
timeFrame: 8 weeks
measure: incremental area under the triglyceride curve (iAUC-TG)
timeFrame: 8 weeks
measure: LDL-cholesterol
timeFrame: 8 weeks
measure: HDL-cholesterol
timeFrame: 8 weeks
measure: triglyceride
timeFrame: 8 weeks
measure: glucose
timeFrame: 8 weeks
measure: HOMA
timeFrame: 8 weeks
measure: insulin
timeFrame: 8 weeks
measure: HbA1c
timeFrame: 8 weeks
measure: area under the glucose curve (AUC-glucose)
timeFrame: 8 weeks
measure: area under the insulin curve (AUC-insulin)
timeFrame: 8 weeks
measure: endothelial function
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Med Dept. 2 Grosshadern
Study officials:
References:
Clinical trial NCT01875302: Comparison of an Electronic Version of Selected COPD PRO Instruments With the Original Versions
Official title: Comparison of an Electronic Version of Selected COPD PRO Instruments With the Original Versions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COPD
Keywords: COPD PRO Instraments equivalency
Lead sponsor: nSpire Health, Inc.
Sponsor class: INDUSTRY
First posted: 2013-06-11
Enrollment: 20
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: COPD Subjects

Brief summary: This protocol defines the requirements to demonstrate that the PRO instruments which were designed as paper-based are equivalent to the nSpire Health ePRO (electronic patient reported outcome), following the ISPOR's ePRO Good Research Practices Task Force recommendations. All validation studies of the questionnaires were conducted using the original paper versions.


Eligibility criteria: Inclusion Criteria:

* Give their signed written informed consent to participate
* Current symptoms COPD, as diagnosed by a physician
* Age 40 - 75 years
* Able to read and understand English

Exclusion Criteria:

• Unwilling to complete the 3 electronic PRO questionnaires or participate in an interview during completion of questionnaires

Primary outcomes:
measure: Demonstrate that the following PRO instruments which were designed as paper-based are equivalent to the nSpire Health ePRO (electronic patient reported outcome)
timeFrame: 60 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: nSpire Health
name: Michelle Vig, MS
role: STUDY_DIRECTOR
References:
Clinical trial NCT05899621: A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Official title: A Real-world Study of the Efficacy and Safety of Obinutuzumab-based Therapy for Previously Untreated Follicular Lymphoma
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Follicular Lymphoma
Keywords: obinutuzumab
Lymphoma
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2023-06-12
Enrollment: 332
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients age ≥18 years with grade 1 to 3a FL.

Brief summary: This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma

Detailed description: This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.

Eligibility criteria: Inclusion Criteria:

* Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification
* Treatment naive
* Age ≥ 18 years
* Indications for treatment confirmed
* Must has measurable lesion in CT or PET-CT prior to treatment
* Considered suitable for GR, GB or GCHOP regimens
* Informed consented

Exclusion Criteria:

* Transformed follicular lymphoma or 3B follicular lymphoma;
* HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive
* Central nervous system or meninges involved
* Any drug contraindication in the treatment plan
* Patients judged by other researchers to be unsuitable for inclusion in the study

Primary outcomes:
measure: Objective response rate (ORR)
timeFrame: End of treatment visit (6 weeks after last dose on Day 1 of Cycle 6 [Cycle length=21 days]
Secondary outcomes:
measure: Complete response rate (CR)
timeFrame: End of treatment visit (6 weeks after last dose on Day 1 of Cycle 6 [Cycle length=21 days]
measure: Progression free survival
timeFrame: Baseline up to data cut-off (up to approximately 2 years)
measure: Duration of response
timeFrame: Baseline up to data cut-off (up to approximately 2 years)
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
state: Shanghai
Study officials:
affiliation: Ruijin Hospital
name: Weili Zhao
role: STUDY_CHAIR
References:
Clinical trial NCT02765321: Populational Program of Physical Activity and Healthy Eating Promotion: the "Life of Health" Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Health Behavior
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2016-05-06
Enrollment: 10000
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This is a population-based "natural experiment" study aimed to examine the effect of a multi-approach intervention focused on physical activity and healthy eating promotion to individuals living in Jaguariuna city (São Paulo, Brazil).


Eligibility criteria: Inclusion Criteria:

* citizens from Jaguariuna city (Sao Paulo, Brazil)

Exclusion Criteria:

* citizens not from Jaguariuna city (Sao Paulo, Brazil)
* children below 8 years of age.

Primary outcomes:
measure: waist circumference
timeFrame: 7 months
Secondary outcomes:
measure: fasting glycemia
timeFrame: 7 months
measure: fasting insulinemia
timeFrame: 7 months
measure: total cholesterol
timeFrame: 7 months
measure: LDL-cholesterol
timeFrame: 7 months
measure: HDL-cholesterol
timeFrame: 7 months
measure: triglycerides
timeFrame: 7 months
measure: VLDL-cholesterol
timeFrame: 7 months
measure: C-reactive protein
timeFrame: 7 months
measure: objectively measured physical activity levels
timeFrame: 7 months
measure: subjectively measured physical activity levels
timeFrame: 7 months
measure: subjectively measured physical activity levels
timeFrame: 7 months
measure: food intake
timeFrame: 7 months
measure: blood pressure
timeFrame: 7 months
measure: body mass index
timeFrame: 7 months
measure: self-perceived health status
timeFrame: 7 months
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: University of Sao Paulo
Study officials:
affiliation: University of Sao Paulo
name: Fabiana B Benatti, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Casa do BemStar Marcio Atalla
name: Marcio Atalla
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Sao Paulo
name: Evelyn F Costa, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Sao Paulo
name: Alex Florindo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03263221: Traumatic Proximal Femoral Fractures in Adults
Official title: Traumatic Proximal Femoral Fractures in Adults
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Proximal Humeral Fracture
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-08-28
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 48
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adults patients with proximal femoral fractures

Brief summary: Statistical analysis for adult patients who were admitted to Assiut university hospital within one year with proximal femoral fractures.

Protocol of management include lines of treatment , hospital stay and results

Detailed description: Case series prospective study All adult patients who were admitted to AUH with proximal femoral fractures within one year.

We will evaluate the real treatment protocol which was applied for those patients.

Surgical procedures, as plating, Proximal Femoral Nail , Dynemic Hip screw and others procedures according to needed for each types.

This epidemological study in proximal femoral fractures will provide an update on incidence, admission, hospital stay and surgical procedures. This information will assist health providers in planning hospital beds, surgical intervention, and risk prevention, moreover, this data can be use for farther clinical studies.

Eligibility criteria: Inclusion Criteria:

* 1-Adult Age 2- Closed \& Open fracture

Exclusion Criteria:

* 1- Childern 2-pathological fractures

Primary outcomes:
measure: • Statistical analysis for adult patients who were admitted to Assiut university hospital within one year with proximal femoral fractures
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06045884: FNB in Meniscal Tear Under GA
Official title: Effects of Sono-guided Femoral Nerve Block in Arthroscopic Surgery for Meniscal Tear Under General Anesthesia: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Meniscus Tear
Femoral Nerve Block
Keywords: Femoral Nerve Block
Meniscus Tear
Lead sponsor: Chuncheon Sacred Heart Hospital
Sponsor class: OTHER
First posted: 2023-09-21
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The investigators will compare the results of sono-guided femoral nerve block in arthroscopic surgery for meniscal tear under general anesthesia

Detailed description: This study is a randomized controlled trial of 100 patients, who underwent history taking, physical examinations, x-rays, and MRI or ultrasonography, and were diagnosed with meniscal tear from september 2023 to august 2028. The 100 patients will be assigned to Group I (with femoral nerve block) or Group II (without femoral nerve block) under double-blinded randomization. The randomization will be performed by an independent nurse using a computerized random sequence generator. The operators who participated in the procedure will be blinded to the participant's information. Both group will undergo general anesthesia for arthroscopic meniscal surgery. After anesthesia, sono-guided femoral nerve block will be performed. The injection for group1 is 20 mL ropivacaine and for groupII is 20 mL 0.9% saline. A visual analog scale (VAS) for pain will be recorded 1, 3, 6, 12, 18, 24, 36, 48 hours after the operation. VAS scores range from 0 to 10, with 0 being no pain and 10 being the most severe pain ever experienced. Injection with ultrasonography will be performed by a single anesthesiologist. 3 orthopedic surgeons will perform the surgery.

Eligibility criteria: Inclusion Criteria:

- individuals who are scheduled to undergo meniscal surgery and must be received sufficient explanation about the research prior to surgery and have provided their informed consent to participate.

Exclusion Criteria:

* who require simultaneous surgery for concomitant cartilage injury, collateral ligament tear.
* who have previously undergone surgical treatment within the knee joint.
* who have declined to participate in the research.
* where medical, surgical, or anesthetic complications occurred during surgery.
* other cases deemed necessary by the researchers.

Primary outcomes:
measure: postoperative pain after 24hours
timeFrame: 24hours
Secondary outcomes:
measure: postoperative pain after 1, 3, 6, 12, 18, 48 hours
timeFrame: 1, 3, 6, 12, 18, 48 hours
Other outcomes:
Locations:
city: Chuncheon
country: Korea, Republic of
facility: Chuncheon Sacred Heart Hospital
state: Gangwon-do
Study officials:
References:
Clinical trial NCT04622384: The Performance of Renal Doppler Ultrasound in Predicting Outcome of Dialysis Weaning
Official title: The Performance of Renal Doppler Ultrasound in Predicting Outcome of Dialysis Weaning
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Kidney Injury
Acute Kidney Failure Stage 3
Keywords: Ultrasound
Renal Replacement Therapy
Dialysis
Renal Doppler Ultrasound
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2020-11-10
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted to the ICU, Aarhus University Hospital who are treated with dialysis as CRRT and planned to undergo dialysis weaning as determined their attending ICU physician.

Brief summary: Acute kidney injury (AKI) is a frequent problem in the intensive care unit (ICU) affecting more than 50 % of patients. AKI is associated with several adverse outcomes, including increased mortality and increased length of ICU- and hospital stay, in particular in patients requiring Renal Replacement Therapy (RRT).

Choosing the optimal time for attempting liberation from RRT is still unclear. With this study, we will describe the ability of renal ultrasound in predicting the outcome of dialysis weaning.


Eligibility criteria: Inclusion Criteria:

* All patients ≥ 18 years admitted to the ICU, Aarhus University Hospital who are treated with dialysis as continuous renal placement therapy (CRRT) and planned to undergo dialysis weaning

Exclusion Criteria:

* Insufficient ultrasonographic imaging of the kidneys
* Known morphological kidney disease
* Previous need of chronic RRT
* Prior participation in the study
* Need of extracorporeal membrane oxygenation (ECMO) or other heart assist device

Primary outcomes:
measure: Dialysis weaning
timeFrame: 7 days
Secondary outcomes:
measure: Renal Doppler arterial Resistive Index (RI)
timeFrame: Measured at the beginning of weaning and after 6 hours.
measure: Renal Doppler Renal Venous Stasis Index (RVSI)
timeFrame: Measured at the beginning of weaning and after 6 hours.
measure: Renal Doppler Venous Impedance Index (VII)
timeFrame: Measured at the beginning of weaning and after 6 hours.
measure: Portal vein Doppler Pulsatility Fraction PF)
timeFrame: Measured at the beginning of weaning and after 6 hours.
measure: Urine Output
timeFrame: 4 days
measure: Urine Creatinine Clearance
timeFrame: 4 days
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital, Department of Anaesthesiology
Study officials:
affiliation: Aarhus University Hospital
name: Peter Juhl-Olsen, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00227084: Effect of Arista Powder on Bleeding in Reductive Mammary Surgery
Official title: Effect of Arista AH-Haemostatic Powder in Plastic Surgery. A Prospective, Consecutive Randomized Study in 30 Women Undergoing Reduction of Both Mamma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Mammaplasty
Keywords: Mammary glands
hemostasis
Mammaplasty
Lead sponsor: University of Oslo
Sponsor class: OTHER
Collaborators: name: Ullevaal University Hospital
name: Medafor
First posted: 2005-09-27
Enrollment: 30
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To evaluate whether Arista AH which contains microporous polysaccharides used as a powder applied to the wound area during mammary surgery reduces the amount of bleeding and the duration of surgery. Both mammae are operated on in the same procedure, and one side without Arista serves as control side

Detailed description: During the operation,before the first incision a randomization envelope is opened. Always starts on the same side, with or without Arista according to the envelope. After surgery, vacuum drains are placed and the amount of drained material and hgb content is measured 24 hours later by nursing staff blinded to what side had Arista.Patients scores postoperative pain with VAS score bilaterally.

Three months postoperatively the patients are checked by a physician blinded for what side had Arista

Eligibility criteria: Inclusion Criteria:

* All women for mammary hypertrophy day surgery. No exclusions in this group.

Primary outcomes:
measure: duration of surgery
measure: amount of bleeding on drain
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Ulleval University Hospital
Study officials:
affiliation: Ullevaal University Hospital
name: Christian Askenberg, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Oslo
name: Petter A Steen, MD,PhD
role: STUDY_DIRECTOR
References: